American regulators granted approval on Wednesday to a gene-altering treatment for patients suffering from lymphoma, the second-ever approval for a gene therapy procedure and one that could revolutionize how we fight cancer. The drug, named Yescarta, was developed by Israeli-founded Kite Pharma and it is expected to cost some $373,000, likely generating hundreds of millions of dollars in sales. Kite was purchased by Gilead Sciences in August to the tune of $11.9 billion, and today’s breakthrough may have helped with the sale. The price of Yescarta is set below that of comparable treatments, according to Reuters, as Novartis AG’s gene...
